No. | Sample | AN | AM | CZ | CTX | CAZ | TGC | GM | TZP | AMC | AZM | FEP | FOX | ETP | CIP | IPM | SXT | NAL |
---|
2017-12-30 | blood | <=2 | 4 | <=4 | <=1 | <=1 | 1 | <=1 | <=4 | <=2 | <=1 | <=1 | <=4 | <=0.5 | 1 | <=0.25 | <=20 | 128< |
interpretations | R | S | R | S | S | S | R | S | S | S | S | R | S | R | S | S | R |
2018-01-03 | bone Biopsy | <=2 | 4 | <=4 | <=1 | <=1 | 2 | <=1 | <=4 | <=2 | <=1 | <=1 | <=4 | <=0.5 | 1 | <=0.25 | <=20 | 128< |
interpretations | R | S | R | S | S | S | R | S | S | S | S | R | S | R | S | S | R |
- Nalidixic acid was tested at the Health and Environment Research Institute, and the remaining interpretations were obtained at Chosun University Hospital
- AN Amikacin, AM Ampicillin, CZ Cefazolin, CTX Cefotaxime, CAZ Ceftazidime, TGC Tigecycline, GM Gentamicin, TZP Piperacillin/Tazobactam, AMC Amoxicillin/ClavulanicAcid, AZM Aztreonam, FEP Cefepime, FOX Cefoxitin, ETP Ertapenem, CIP Ciprofloxacin, IPM Imipenem, SXT Trimethoprim/Sulfamethoxazole, NAL Nalidixic acid